Antiangiogenic peptides

US7655626B2 · kind B2 · utility

Assignees

• UNIVERSITE DE LIEGE · BE
• Faculte Universitaire des Sciences Agronomiques de Gembloux · BE

Inventors

• Joseph Martial · Modave, BE
• Ingrid Struman · Boncelles, BE
• Ngoc-Quynh-Nhu Nguyen · Ans, BE
• Robert Brasseur · Haillot, BE
• Laurence Lins · Vieusart, BE

Key dates

• Filing date: Aug 11, 2005
• Grant date: Feb 2, 2010
• Expiry date: Aug 29, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/15022
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.